100P Hepatitis B virus (HBV)-related outcomes in patients (pts) with baseline HBV infection in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)
Stephen L. Chan(Prince of Wales Hospital), Richard S. Finn(University of California, Los Angeles), Juan W. Valle(The Christie NHS Foundation Trust), Robin Kate Kelley(University of California, San Francisco), Changhoon Yoo(Asan Medical Center), Junji Furuse(Kyorin University Hospital), Zhenggang Ren(Fudan University), Thomas Yau(University of Hong Kong), Heinz‐Josef Klümpen(Amsterdam University Medical Centers), Masato Ozaka(Japanese Foundation For Cancer Research), Chris Verslype(Universitair Ziekenhuis Leuven), Mohamed Bouattour(Hôpital Beaujon), J.O. Park(Samsung Medical Center), Julien Edeline(Centre Eugène Marquis), Makoto Ueno(Kanagawa Cancer Center), Arndt Vogel(Medizinische Hochschule Hannover), Li Yu(Decision Sciences (United States)), Usha Malhotra(Merck & Co., Inc., Rahway, NJ, USA (United States)), A.B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shukui Qin
Cited by 1
Abstract
Related Papers
No related papers found
Powered by citation graph analysis